Delgocitinib cream significantly improved chronic hand eczema in adult patients, according to topline results from the DELTA 1 study.

The phase 3 study ( Identifier: NCT04871711) compared delgocitinib cream, a topical pan-Janus kinase (JAK) inhibitor, to vehicle in patients with moderate to severe chronic hand eczema. The primary endpoint was the Investigator’s Global Assessment for chronic hand eczema (IGA-CHE) treatment success at week 16. Treatment success was defined as an IGA-CHE score of 0 (clear) or 1 (almost clear, with little or no disease left) with at least a 2-step improvement from baseline.

Findings showed that the trial met its primary endpoint with a significantly larger proportion of delgocitinib-treated patients achieving treatment success compared with the vehicle arm. The study also met key secondary endpoints including a reduction of itch and pain scores of at least 4 points (as measured by the Hand Eczema Symptom Diary), as well as at least 75% improvement from baseline and at least 90% improvement from baseline on the Hand Eczema Severity Index at week 16.

Continue Reading

“There are currently no topical treatments specifically developed and approved for the treatment of moderate to severe [chronic hand eczema], making it a challenging disease to treat,” said Jörg Möller, Executive Vice President, Global Research & Development, LEO Pharma. “We are encouraged by these top-line phase 3 trial results, which show that delgocitinib cream provided fast symptom-relief and could be an efficacious and well-tolerated treatment solution, helping adults suffering from moderate to severe [chronic hand eczema] to regain their social and occupational lives.”

Delgocitinib cream is also being evaluated for chronic hand eczema in the ongoing phase 3 DELTA 2 study ( Identifier: NCT04872101).


LEO Pharma announces positive phase 3 topline results from DELTA 1 trial with delgocitinib cream in adults with moderate to severe chronic hand eczema (CHE). News release. December 6, 2022.

This article originally appeared on MPR